How To Make Decisions On What Meds To Take?
How To Make Decisions On What Meds To Take?
Hi, I’m Jim Berenson from the Institute for Myeloma & Bone Cancer Research.
I’d like to discuss how do you decide what medications to take for your myeloma? Well, this wasn’t so complicated just thirty years ago. We didn’t have a lot to try. We had chemotherapeutic drugs and maybe steroids. But over the last thirty years there has been an explosion of new drugs to treat myeloma, and luckily, combinations of drugs. So, we were fortunate that when we combined drugs together, we learned that they were not only more effective, but we could use them at lower doses. That meant if one drug caused a nerve problem, another one possibly caused a heart problem – but, by reducing the doses of both drugs, patients would have less nerve problems and fewer heart problems. So, we often do that in our clinic – we have patients that not only get effective therapy, but their quality of life is maintained while they’re on their treatment. Now you as a patient may not want to put up with certain potential side effects. Therefore, you’ll need to discuss that with your doctor to avoid those drugs or receive them at lower doses. For example, some of the drugs cause nerve problems. Well, if you’re a pianist, you don’t want that or if you’re a surgeon, you certainly don’t want that either. If you have a heart condition, you may have to take certain drugs as well. Then, of course if you’re an active person and you travel a lot, you don’t want to come to clinic all the time. So, you might prefer pills to drugs. But over time, your options may become more limited, so you may have to balance the benefit of the convenience of the treatment versus the side effects. We also know that patients with myeloma get a lot of drugs; in my opinion, too many in a lot of cases. So, it’s important for myeloma patients to be specific about how much you will really need to take for the drugs to be effective. You may not need that much if you’re not that sick with myeloma. On the other hand, if you have a very tough form of myeloma, with poor blood counts or compromised kidney function, you may need more treatment. You’re going to have to put up with those potential side effects. So, all of this needs to be taken into account as you decide what kind of treatment you’re going to need for your specific myeloma.
How Long Should Patients Stay On Treatment?
Hi, I’m Jim Berenson from the Institute for Myeloma & Bone Cancer Research.
I’d like to discuss how long patients should stay on treatment for myeloma. Well, that is a great question and it’s very complicated to answer.
We believe that myeloma patients need to stay on a therapy that they can tolerate with minimal impact on their quality of life. Most importantly, the treatment needs to control their myeloma and its associated complications. What does that specifically mean? Well, early on patients are going to be getting more intensive therapy. They will be receiving more drugs at higher doses over a number of months. However, once their disease is under control, they may be able to reduce the intensity of the therapy. They may be able to stop taking some drugs. Most of the time, patients are continued on treatment to keep their disease under control. That is, they receive what’s called maintenance therapy. Drugs should not be stopped altogether because we know that keeping treatment going allows patients to have a better outcome. They will live longer with a better quality of life and that’s the goal.
But, at the same time, we may be able to lower the doses and increase the time between doses of some drugs once the disease is under control. We don’t really know how low patients can go with the amount of drug. There have been very few studies looking at the lowest dose that remains effective for most drugs. But, once patients lose the ability to control their myeloma on maintenance therapy, they may be able to regain control of their disease simply by increasing the dose of some drugs or adding other drugs into their therapy or they may need to switch their treatment altogether. This may require more frequent visits to the clinic. However, in some cases patients might switch to orally administered drugs; and, therefore, might be able to come less often into the clinic for their treatment. Once their disease is controlled, they may continue treatment with less drugs at lower doses and be able to maintain remission for a long period of time.
So, there’s a series of ups and downs with the doses and intensity and how often patients have to come into the doctor’s office. But, in general they’re going to stay on therapy. Now some individuals are going to say, “No, I’m done. I’m going to stop therapy altogether.” Occasionally, they’ll do just fine with that approach, but we don’t believe that drug holidays are going to be to most patients’ benefit in the long run to achieve optimal control of their myeloma for the longest period of time.
Thus, staying on treatment is pretty important. Finding a treatment that not only works, but one that patients can live with as well is equally important!
Myeloma Monthly – Myeloma Bone Disease
Hi, I’m Jim Berenson from the Institute of Myeloma & Bone Cancer Research.
I’d like to discuss with you today Myeloma Bone Disease. Bone-related problems are the most important thing that happens to a myeloma patient clinically. Why? Because the bone marrow where myeloma resides is right next to bone, and often, the bone marrow itself when crowded with myeloma cells causes a negative impact on bone strength. And how does that occur? It occurs because there are types of cells called osteoclasts in the bone marrow that are like Pac-Men that gobble up bones. So what does that do? It weakens the bones, so patients have fractures. The bones can expand from the myeloma pushing on them so patients experience bone pain. All of this often leads to the requirement for pain medication, surgery and sometimes radiation treatments. And sometimes the spinal cord can be impacted by crushing the vertebral bodies or myeloma tumors in the back. That can lead to more serious problems like paraplegia which is paralysis of the legs.
So how do we stop that from happening? Well, there are multiple ways we can do that, easy ways such as maintaining your Vitamin D levels. It is important to have your doctor check that. You should be taking supplemental Vitamin D and calcium. Although calcium levels can be higher in severe bone disease from leeching calcium out of bone, most patients actually require supplemental calcium. So, the use of calcium and Vitamin D are most helpful in maintaining bone strength. Second, there are drugs we use today to help prevent bone loss. First, we had intravenously administered bisphosphonates. In earlier days, it was Aredia or pamidronate, and more recently over the last 30 years it’s been Zometa or zoledronic acid. A monthly infusion makes bones stronger. How do these drugs work? They eliminate the Pac-Men, stopping them from gobbling up bones. So, the bones are stronger and less likely to fracture. We also now have available a newer drug for myeloma bone disease called XGEVA (or denosumab), an antibody that reduces the number of osteoclasts, so there is less bone loss resulting in stronger bones. So, one can use either of these types of drugs, the bisphosphonates or XGEVA. However, the latter is markedly more expensive and doesn’t work any better than the bisphosphonates. Importantly, XGEVA doesn’t cause kidney problems which can sometimes occur from administration of either Aredia or Zometa. So, for patients who have kidney problems, we now have an option to treat their bone disease, we have XGEVA.
In addition, it’s important for the myeloma itself to be treated. Eliminating the myeloma cells in the bone marrow prevents them from stimulating the Pac-Men and their ability to gobble up bones. Thus, we have a multi-pronged approach in myeloma patients to prevent bone loss, fractures, and bone pain. We have Vitamin D. We have calcium. We have drugs like bisphosphonates and XGEVA and we have treatment for the myeloma itself. As a result of this multi-pronged approach, bony complications have been markedly reduced among myeloma patients over the last two decades.